A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of
saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with
saredutant 100 mg once daily.
The secondary objective is to evaluate the safety and tolerability of 8 weeks of open-label
treatment with saredutant 100 mg once daily in outpatients with depression.